Want to see HK:8158 full AI Analyst Report?

China Regenerative Medicine International Limited (8158) Price & Analysis

0 Followers

8158 Stock Chart & Stats

HK$0.41

HK$0.00(0.00%)

At close: Jan 06 4:00 PM EST

HK$0.41

HK$0.00(0.00%)

Day’s Range― - ―

52-Week RangeHK$0.06 - HK$0.73

Previous CloseN/A

Volume500.00

Average Volume (3M)52.34K

Market Cap

HK$89.75M

Enterprise ValueHK$130.75

Total Cash (Recent Filing)HK$1.82M

Total Debt (Recent Filing)HK$38.25M

Price to Earnings (P/E)3.0

Beta0.10

Next Earnings

Apr 01, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.10

Shares Outstanding304,252,470

10 Day Avg. Volume117,042

30 Day Avg. Volume52,345

Financial Highlights & Ratios

PEG Ratio0.08

Price to Book (P/B)2.39

Price to Sales (P/S)1.77

P/FCF Ratio31.74

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth And ProfitabilityTTM revenue growth of 35.39%, paired with gross and net margins near 56% and 28%, indicates current operating momentum with meaningful profitability. If sustained, this combination can support reinvestment and strengthen the company’s ability to build earnings over coming quarters.

Improved LeverageDebt-to-equity fell from about 4.26x in 2023 and 2.13x in 2024 to 0.67x TTM, while equity rebuilt from stressed periods. This materially improves financial flexibility and reduces the burden that previously constrained resilience and capital allocation.

Stronger Free Cash FlowTTM operating and free cash flow were both about 15.6M, with FCF growth of roughly 58.9% and cash generation broadly aligned with recent profit. Better conversion strengthens earnings quality and gives the business more internally generated funding for ongoing needs.

Bears Say

Volatile Revenue And ResultsDespite current growth, revenue has shown sharp declines and large swings across 2022–2025, while the company moved through a major 2023 loss. Such volatility makes forecasting less reliable and raises the risk that current growth and margins may not persist.

Inconsistent Cash ConversionOperating cash flow was negative in 2021–2022 and conversion was low in 2025; the pack also identifies historically low operating cash flow relative to net income. This uneven cash conversion can weaken funding reliability even when reported profits are positive.

Earnings Quality Risk2025 profitability occurred alongside negative EBIT, which signals that reported earnings may not fully reflect underlying operating performance. This discrepancy is a durable earnings-quality concern because it can make margins, profit sustainability, and future cash generation harder to assess.

8158 FAQ

What was China Regenerative Medicine International Limited’s price range in the past 12 months?

China Regenerative Medicine International Limited lowest stock price was HK$0.06 and its highest was HK$0.73 in the past 12 months.

What is China Regenerative Medicine International Limited’s market cap?

China Regenerative Medicine International Limited’s market cap is HK$89.75M.

When is China Regenerative Medicine International Limited’s upcoming earnings report date?

China Regenerative Medicine International Limited’s upcoming earnings report date is Apr 01, 2027 which is in 181 days.

How were China Regenerative Medicine International Limited’s earnings last quarter?

China Regenerative Medicine International Limited released its earnings results on Aug 21, 2026. The company reported HK$0.015 earnings per share for the quarter.

Is China Regenerative Medicine International Limited overvalued?

According to Wall Street analysts China Regenerative Medicine International Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does China Regenerative Medicine International Limited pay dividends?

China Regenerative Medicine International Limited does not currently pay dividends.

What is China Regenerative Medicine International Limited’s EPS estimate?

China Regenerative Medicine International Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does China Regenerative Medicine International Limited have?

China Regenerative Medicine International Limited has 304,252,470 shares outstanding.

What happened to China Regenerative Medicine International Limited’s price movement after its last earnings report?

China Regenerative Medicine International Limited reported an EPS of HK$0.015 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of China Regenerative Medicine International Limited?

Currently, no hedge funds are holding shares in HK:8158

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

China Regenerative Medicine International Limited

China Regenerative Medicine International Limited operates as an investment holding entity, focusing on the development and distribution of a diverse portfolio of healthcare products and associated services. The company provides extensive health management solutions, covering health condition assessments, detoxification programs, fostering internal bodily balance, nourishing vital organs, and enhancing the immune system. Additionally, its beauty offerings encompass non-surgical medical aesthetics, essential dermatological care, anti-aging skin remedies, hair revitalization, skin firming treatments, localized body contouring, and intimate restoration services. Established in 1995, the organization was previously known as China Bio-Med Regeneration Technology Limited until its rebranding to China Regenerative Medicine International Limited in March 2015. Its headquarters are situated in Tsim Sha Tsui, Hong Kong.